Study summary

CAR T cells targeting half of T cells produced complete responses without wiping out immunity

LibraT1 trial (TRBC1 CAR T cells) · 10 people, phase 1/2 · Published November 2024, Nature Medicine

What was tested

AUTO4, CAR T cells aimed at TRBC1, a marker found on only one of two T-cell families, so lymphoma cells can be targeted while sparing half of healthy T cells.

What they found

• 4 of 10 had a complete metabolic response, two lasting beyond a year.
• Only one had severe cytokine release syndrome.

What it means

Solves a key problem for T-cell CAR therapy: avoiding destruction of all healthy T cells.